Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Iterum Therapeutics Plc (ITRM)

Iterum Therapeutics Plc (ITRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,270
  • Shares Outstanding, K 12,233
  • Annual Sales, $ 0 K
  • Annual Income, $ -91,560 K
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade ITRM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.15
  • Number of Estimates 1
  • High Estimate -1.15
  • Low Estimate -1.15
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -155.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2100 +9.92%
on 11/22/22
1.9100 -30.37%
on 10/26/22
-0.4900 (-26.92%)
since 10/25/22
3-Month
1.2100 +9.92%
on 11/22/22
2.8800 -53.82%
on 08/26/22
-1.4900 (-52.84%)
since 08/25/22
52-Week
1.2100 +9.92%
on 11/22/22
7.5150 -82.30%
on 11/26/21
-6.1100 (-82.12%)
since 11/24/21

Most Recent Stories

More News
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports First Quarter 2022 Financial Results

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May ...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Provides Regulatory Update

DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

--Registration Trial for uUTI Planned in Second Half of 2022----Cash Runway into 2024-- --Company to host conference call today at 8:30am ET-- DUBLIN,...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and CHICAGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

ITRM : 1.3300 (+1.92%)
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage...

ITRM : 1.3300 (+1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated...

See More

Key Turning Points

3rd Resistance Point 1.4033
2nd Resistance Point 1.3767
1st Resistance Point 1.3533
Last Price 1.3300
1st Support Level 1.3033
2nd Support Level 1.2767
3rd Support Level 1.2533

See More

52-Week High 7.5150
Fibonacci 61.8% 5.1065
Fibonacci 50% 4.3625
Fibonacci 38.2% 3.6185
Last Price 1.3300
52-Week Low 1.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar